Time intervals from vaccine administration to reimbursement for an updated Advisory Committee on Immunization Practices (ACIP) recommendation: Evidence from pneumococcal conjugate vaccinations among privately insured adults, 2021-2022.

ABSTRACT:

Background

Vaccination implementation challenges can lead to lower uptake, reducing health and economic benefits from vaccines. Healthcare provider confidence in receiving timely reimbursement for vaccination is one such potential challenge for newly recommended vaccines. This study investigates the time interval between pneumococcal vaccination and reimbursement.

Methods

We used 2021-2022 Merative™ MarketScan® Commercial Database and Medicare Database (MarketScan) data among those aged 19-64 and ≥65 years for two vaccines: the 13-valent pneumococcal conjugate vaccine (PCV13), recommended in 2012; and the newer 20-valent PCV (PCV20), recommended in 2021. We characterized vaccination claims, patient demographics, and time intervals between vaccination and reimbursement.

Re

SUBMITTER: Rosenblum HG 

PROVIDER: S-EPMC12614235 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature